ADRB3 and obesity disorder: In recent clinical trials, individuals with obesity and insulin resistance demonstrated improved oxidative metabolism and ameliorated glucose homeostasis following mirabegron (an ADRB3 agonist) treatment (Finlin et al., 2020; O'Mara et al., 2020; Cero et al., 2021; Byun et al., 2022; Valentine et al., 2022).